<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02853864</url>
  </required_header>
  <id_info>
    <org_study_id>Intravenous anesthesia</org_study_id>
    <nct_id>NCT02853864</nct_id>
  </id_info>
  <brief_title>Influence of Gender on Interaction of Propofol and Dexmedetomidine</brief_title>
  <official_title>Influence of Gender on Interaction of Propofol and Dexmedetomidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou General Hospital of Guangzhou Military Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of gender on pharmacodynamic interaction
      of propofol and dexmedetomidine, exploring the effect of gender on propofol unconsciousness
      median effective concentration with different dose dexmedetomidine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 cases male patients were randomly divided into four groups,and 60 female patients were
      also randomly divided into four groups.In each group, dexmedetomidine target plasma
      concentration are 0,0.4,0.6,0.8 ng/ml. Dexmedetomidine administered 15 min before target
      controlled infusion of propofol. The propofol infusion is started to provide a target
      effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of
      consciousness when the effect-site concentration and target concentration are equilibrium.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the effect-site EC50 of propofol on loss of consciousness with different gender</measure>
    <time_frame>within 30 min during the induction of anesthesia</time_frame>
    <description>The aim of the investigators study is to define the optimum target concentration (EC50) of propofol for loss of consciousness with different dexmedetomidine target plasm concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The EC95 of propofol for loss of consciousness with different gender</measure>
    <time_frame>within 30 min during the induction of anesthesia</time_frame>
    <description>The aim of the investigators study is to define the optimum target concentration (EC95) of propofol for loss of consciousness with different dexmedetomidine target plasm concentration.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Propofol and 0.0 ng/ml Dexmedetomidine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.0ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol and 0.4 ng/ml Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.4ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol and 0.6 ng/ml Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.6ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol and 0.8 ng/ml Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.8ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.0 ng/ml Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine target plasma concentration is 0.0 ng/ml</description>
    <arm_group_label>Propofol and 0.0 ng/ml Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.4 ng/ml Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine target plasma concentration is 0.4 ng/ml</description>
    <arm_group_label>Propofol and 0.4 ng/ml Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.6 ng/ml Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine target plasma concentration is 0.6 ng/ml</description>
    <arm_group_label>Propofol and 0.6 ng/ml Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.8 ng/ml Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine target plasma concentration is 0.8 ng/ml</description>
    <arm_group_label>Propofol and 0.8 ng/ml Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness</description>
    <arm_group_label>Propofol and 0.0 ng/ml Dexmedetomidine</arm_group_label>
    <arm_group_label>Propofol and 0.4 ng/ml Dexmedetomidine</arm_group_label>
    <arm_group_label>Propofol and 0.6 ng/ml Dexmedetomidine</arm_group_label>
    <arm_group_label>Propofol and 0.8 ng/ml Dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Weight:18≦ BMI≦25

          2. Written informed consent from the patient or the relatives of the participating
             patient.

        Exclusion Criteria:

          1. A previous history of intolerance to the study drug or related compounds and
             additives.

          2. Existing significant haematological, endocrine, metabolic or gastrointestinal disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guangzhou Military Region General Hospital, Department of Anesthesiology</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kodaka M, Johansen JW, Sebel PS. The influence of gender on loss of consciousness with sevoflurane or propofol. Anesth Analg. 2005 Aug;101(2):377-81, table of contents.</citation>
    <PMID>16037147</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou General Hospital of Guangzhou Military Command</investigator_affiliation>
    <investigator_full_name>bo xu</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <keyword>Gender</keyword>
  <keyword>Propofol</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

